1
|
Li JJ. Tafolecimab, A Novel Member of PCSK9 Monoclonal Antibodies, Is Worth Expecting in a Chinese Population. JACC Asia 2023; 3:646-648. [PMID: 37614538 PMCID: PMC10442878 DOI: 10.1016/j.jacasi.2023.06.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/15/2023]
Affiliation(s)
- Jian-Jun Li
- Cardiometabolic Center, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| |
Collapse
|
2
|
Qi L, Liu D, Qu Y, Chen B, Meng H, Zhu L, Li L, Wang S, Liu C, Zheng G, Lian Q, Yin G, Lv L, Lu D, Chen X, Xue F, An P, Li H, Deng H, Li L, Qian L, Huo Y. Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial. JACC Asia 2023; 3:636-645. [PMID: 37614541 PMCID: PMC10442872 DOI: 10.1016/j.jacasi.2023.04.011] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/16/2022] [Revised: 04/05/2023] [Accepted: 04/12/2023] [Indexed: 08/25/2023]
Abstract
Background Tafolecimab is a novel fully human proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody, developed for the treatment of hypercholesterolemia. Objectives The purpose of this study was to assess the efficacy and safety of tafolecimab in Chinese patients at high or very high cardiovascular risk with hypercholesterolemia. Methods Patients with diagnoses of heterozygous familial hypercholesterolemia (HeFH) by the Simon Broome criteria or at high or very high cardiovascular risk with nonfamilial hypercholesterolemia, with screening low-density lipoprotein cholesterol (LDL-C) level ≥1.8 mmol/L, were randomized 2:1 to receive tafolecimab or placebo 450 mg every 4 weeks (Q4W) in the 12-week double-blind treatment period. The primary endpoint was the percent change from baseline to week 12 in LDL-C levels. Results A total of 303 patients were enrolled and received at least 1 dose of tafolecimab (n = 205) or placebo (n = 98). The least squares mean percent change in LDL-C level from baseline to week 12 was -68.9% (SE 1.4%) in the tafolecimab group and -5.8% (1.8%) in the placebo group (difference: -63.0%; [95% CI: -66.5% to -59.6%]; P < 0.0001). More patients treated with tafolecimab achieved ≥50% LDL-C reductions, LDL-C <1.8 mmol/L, and LDL-C <1.4 mmol/L at week 12 than did those in the placebo group (all P < 0.0001). Furthermore, tafolecimab markedly reduced non-HDL-C, apolipoprotein B, and lipoprotein(a) levels. During the double-blind treatment period, the most commonly reported adverse events included urinary tract infection (5.9% with tafolecimab vs 4.1% with placebo) and hyperuricemia (3.4% vs 4.1%). Conclusions Tafolecimab was safe and showed robust lipid-lowering efficacy in Chinese patients at high or very high cardiovascular risk with hypercholesterolemia. (A Study of IBI306 in Participants With Hypercholesterolemia; NCT04709536).
Collapse
Affiliation(s)
- Litong Qi
- Department of Cardiology, Peking University First Hospital, Beijing, China
| | - Dexue Liu
- Department of Endocrinology, The First Affiliated Hospital of Nanyang Medical College, Nanyang, China
| | - Yanling Qu
- Department of Cardiology, Yuncheng Central Hospital of Shanxi Province, Yuncheng, China
| | - Beijian Chen
- Department of Cardiology, Heze Municipal Hospital, Heze, China
| | - Haiyan Meng
- Department of Cardiology, Shandong Provincial Third Hospital, Jinan, China
| | - Lei Zhu
- Department of Cardiology, Shandong Provincial Third Hospital, Jinan, China
| | - Lipeng Li
- Department of Cardiology, Luoyang Third People's Hospital, Luoyang, China
| | - Shuqing Wang
- Department of Cardiology, The First Hospital of Qiqihar City, Qiqihar, China
| | - Changyi Liu
- Department of Cardiology, The First Hospital of Qiqihar City, Qiqihar, China
| | - Guanzhong Zheng
- Department of Cardiology, Zibo Municipal Hospital, Zibo, China
| | - Qiufang Lian
- Department of Cardiology, Yan'an University Xianyang Hospital, Xianyang, China
| | - Guotian Yin
- Department of Cardiology, The Third Affiliated Hospital of Xinxiang Medical College, Xinxiang, China
| | - Lingchun Lv
- Department of Cardiology, Lishui Central Hospital, Lishui, China
| | - Di Lu
- Department of Cardiology, China National Petroleum Corporation Central Hospital, Langfang, China
| | - Xiaoshu Chen
- Department of Cardiology, Wenzhou People's Hospital, Wenzhou, China
| | | | - Pei An
- Innovent Biologics, Inc, Suzhou, China
| | - Haoyu Li
- Innovent Biologics, Inc, Suzhou, China
| | - Huan Deng
- Innovent Biologics, Inc, Suzhou, China
| | - Li Li
- Innovent Biologics, Inc, Suzhou, China
| | - Lei Qian
- Innovent Biologics, Inc, Suzhou, China
| | - Yong Huo
- Department of Cardiology, Peking University First Hospital, Beijing, China
| |
Collapse
|